ctDNA guiding adjuvant immunotherapy in urothelial carcinomaThomas Powles, Sanjeev Mariathasan, Hiroyuki Nishiyama et al.|Nature|2021Cited by 603
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trialJoaquim Bellmunt, Thomas Powles, Maha Hussain et al.|The Lancet Oncology|2021Cited by 411
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial CarcinomaThomas Powles, Sanjeev Mariathasan, Zoe J. Assaf et al.|European Urology|2023Cited by 128
Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative ReviewYair Lotan, Ellen C. Zwarthoff, Peter C. Black et al.|European Urology Oncology|2018Cited by 30
Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter TrialYair Lotan, Stephen A. Boorjian, Brant A. Inman et al.|The Journal of Urology|2019Cited by 27